Federal Register / Vol. 60, No. 55 / Wednesday, March 22, 1995 / Notices 15147

2. Blumberg Bank, L.P. Seguin, Texas;

to become a bank holding company by

acquiring 48 percent of the voting shares

of Seguin State Bank & Trust Company,

Seguin, Texas.

Board of Governors of the Federal Reserve

System, March 16, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–7012 Filed 3–21–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Administration for Children and

Families

Agency Information Collection Under

OMB Review

Under the provisions of the

Paperwork Reduction Act (44 U.S.C.

Chapter 35), the Administration for

Children and Families (ACF) has

submitted to the Office of Management

and Budget (OMB) a request for the

continued use of an information

collection titled: ACF–231–Aid To

Families With Dependent Children

Financial Report; Expenditures and

Estimates.

Addresses: Copies of the request for

approval may be obtained from Robert

A. Sargis of the Office of Information

Systems Management, ACF, by calling

(202) 690–7275.

Consideration will be given to

comments and suggestions received

within 60 days of publication. Written

comments and recommendations for the

proposed information should be sent

directly to the following: Wendy Taylor,

Office of Information and Regulatory

Affairs, Office of Management and

Budget, Docket Library, Room 10102,

725 17th Street, N.W., Washington, D.C.

20503, (202) 395–7316.

Information on Document

Title: ACF—231 AID TO FAMILIES

WITH DEPENDENT CHILDREN

FINANCIAL REPORT

OMB No.: 0970–0032

Description: The information collected

is required by the Social Security Act

to collect program and financial data

under the AFDC program The State

agency provides a quarterly estimate

of the total amount and the Federal

share of expenditures to be made in

administering the AFDC programs.

Respondents: State governments

Annual Number of Respondents: 54

sites

Number of responses per respondent: 6

Total annual responses: 324 sites

Hours per response: 3.5

Total Burden Hours: 1,134

Dated: March 16, 1995.

Roberta Katson,

Acting Director, Office of Information

Resource Management.

[FR Doc. 95–7055 Filed 3–21–95; 8:45 am]

BILLING CODE 4184–01–M

Centers for Disease Control and

Prevention (CDC)

The National Center for Environmental

Health (NCEH) of the Centers for

Disease Control and Prevention (CDC)

Will Convene the Following Meeting

Sponsored by the Division of

Environmental Health Laboratory

Sciences

Name: Development of Innovative

Technology for Measurement of Lead in

Blood: Meeting of Grant Recipients and

Cooperative Research and Development

Agreement (CRADA) Partners.

Time and date: 8:30 a.m.–11 a.m., May 20,

1995.

Place: Terrace Garden Inn-Buckhead, 3405

Lenox Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by

space available.

Purpose: The primary purpose of this

meeting is to brief the grantees and CDC’s

CRADA partners about CDC expectations for

the grant and CRADA program, to encourage

collaboration among grantees and CRADA

partners and to review progress toward the

objectives of the program.

Matters to be discussed: Topics to be

discussed include objectives of the CDC grant

and CRADA program for the development of

innovative technology for the measurement

of lead in blood, impact of the Clinical

Laboratory Improvement Act on the

technology, and an overview of each grantee

and CRADA organization.

Agenda items are subject to change as

priorities dictate.

Contact person for more information:

Robert L. Jones, Ph.D., Supervisory Research

Chemist, Nutritional Biochemistry Branch,

Division of Environmental Health Laboratory

Sciences, (F18), NCEH, CDC, 4770 Buford

Highway, NE, Chamblee, Georgia 30341–

3724, telephone 404/488–7991.

Written comments are welcome and should

be received by the contact person no later

than May 10, 1995. Persons wishing to make

oral comments at the meeting should notify

the contact person in writing or by telephone

no later than May 10, 1995. All requests to

make oral comments should contain the

name, address, telephone number, and

organizational affiliation of the presenter.

Depending on the time available and the

number of requests to make oral comments,

it may be necessary to limit the time of each

presenter.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 95–6997 Filed 3–21–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Advisory Committees; Notice of

Meetings

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: This notice announces

forthcoming meetings of public advisory

committees of the Food and Drug

Administration (FDA). This notice also

summarizes the procedures for the

meetings and methods by which

interested persons may participate in

open public hearings before FDA’s

advisory committees.

FDA has established an Advisory

Committee Information Hotline (the

hotline) using a voice-mail telephone

system. The hotline provides the public

with access to the most current

information on FDA advisory committee

meetings. The advisory committee

hotline, which will disseminate current

information and information updates,

can be accessed by dialing 1–800–741–

8138 or 301–443–0572. Each advisory

committee is assigned a 5-digit number.

This 5-digit number will appear in each

individual notice of meeting. The

hotline will enable the public to obtain

information about a particular advisory

committee by using the committee’s 5-

digit number. Information in the hotline

is preliminary and may change before a

meeting is actually held. The hotline

will be updated when such changes are

made.

MEETINGS: The following advisory

committee meetings are announced:

Drug Abuse Advisory Committee

Date, time, and place. April 6 and 7,

1995, 8 a.m., Parklawn Bldg., conference

rooms D and E, 5600 Fishers Lane,

Rockville, MD.

Type of meeting and contact person.

Closed committee deliberations, April 6,

1995, 8 a.m. to 5 p.m.; open public

hearing, April 7, 1995, 8 a.m. to 9 a.m.,

unless public participation does not last

that long; open committee discussion, 9

a.m. to 4 p.m.; Stephen P. Pollitt, Center

for Drug Evaluation and Research (HFD–

9), Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–443–5455, or FDA Advisory

Committee Information Hotline, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), Drug Abuse

Advisory Committee, code 12535.

General function of the committee.

The committee advises on the scientific

and medical evaluation of information

gathered by the Department of Health

and Human Services and the

Department of Justice on the safety,